• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Magellan Health, Inc. (Amendment)

    4/27/21 3:59:03 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care
    Get the next $MGLN alert in real time by email
    SC 13D/A 1 tm2114332d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    MAGELLAN HEALTH, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

     

    (Title of Class of Securities)

     

    559079207

     

    (CUSIP Number of Class of Securities)

     

    Alec N. Litowitz

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    April 23, 2021

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 2 of 9

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Financial LLC

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨

    (b)   x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,289,081

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,289,081

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,289,081

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.96%

    14. 

    TYPE OF REPORTING PERSON

     

    IA; OO

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 3 of 9

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Capital Partners LP

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨

    (b)   x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,289,081

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,289,081

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,289,081

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.96%

    14. 

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 4 of 9

     

    1.

    NAME OF REPORTING PERSON:

     

    Supernova Management LLC

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)    ¨

    (b)   x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,289,081

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,289,081

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,289,081

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.96%

    14. 

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 5 of 9

     

    1.

    NAME OF REPORTING PERSON:

     

    Alec N. Litowitz 

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)    ¨

    (b)   x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,289,081

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,289,081

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,289,081

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.96%

    14. 

    TYPE OF REPORTING PERSON

     

    HC; IN

      

     

     

    SCHEDULE 13D

     

    This Amendment No. 1 (the “Amendment”) relates to the Statement of Beneficial Ownership on Schedule 13D filed jointly by Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”) with the SEC on February 8, 2021, (as amended by this Amendment, the “Schedule 13D”).

     

    Except as set forth below, all Items of the Schedule 13D remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 3.source and amount of funds or other consideration

     

    Item 3 of the Schedule 13D is hereby amended to add the following information for updating:

     

    The aggregate amount of funds used by the Reporting Persons in purchasing the 21,074 Shares reported herein on behalf of Systematic Master Fund have come directly from the assets of the Systematic Master Fund, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $1,963,134 (excluding commissions and other execution-related costs).

     

    ITEM 4.PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is hereby amended to add the following information for updating:

     

    Since the filing of the 13D with the SEC on February 8, 2021, the Reporting Persons sold 105,635 Shares between March 25, 2021 and April 23, 2021 reported herein which consists of 81,700 Shares sold for the benefit of Constellation Fund and 23,935 Shares sold for the benefit of Systematic Master Fund.

     

    The 231 Shares reported herein that were sold short were executed on behalf of certain clients of Magnetar Financial in another strategy unrelated to risk arbitrage.

     

    The 5,317 Shares reported herein were acquired in the ordinary course of business on behalf of certain clients of Magnetar Financial in another strategy unrelated to risk arbitrage to cover its short positions.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 of the Schedule 13D is hereby amended to add the following information for updating:

     

    (a)            As of the close of business April 23, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,289,081 Shares, which consisted of (i) 555,796 Shares held for the benefit of PRA Master Fund, (ii) 600,863 Shares held for the benefit of Constellation Fund; and (iii) 132,422 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 4.96% of the Shares.

     

     

     

    (b)            As of the close of business April 23, 2021, each of the Reporting Persons may have been deemed to have the power to vote and direct the disposition of 1,289,081 Shares, which consisted of (i) 555,796 Shares held for the benefit of PRA Master Fund, (ii) 600,863 Shares held for the benefit of Constellation Fund; and (iii) 132,422 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 4.96% of the Shares.

     

    (c)            Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on NASDAQ and various other trading markets.

     

    (d)            Each of the Reporting Person ceased to have beneficial ownership greater than 5% of the Shares on April 23, 2021.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 27, 2021

     

      magnetar financial llc
       
      By: Magnetar Capital Partners LP, its Sole Member

     

      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      magnetar capital partners LP

     

      By: /s/ Alec N. Litowitz
        Name:  Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      supernova management llc

     

      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager

     

      /s/ Alec N. Litowitz
      Alec N. Litowitz
       

     

     

     

    SCHEDULE A

     

    Funds

     

    Date  Number of Shares Bought   Price Per Share($) (1)(2) 
    3/3/2021   6,774    92.97343(3)
    3/4/2021   14,300    93.23956(4)
    3/24/2021   5,317    93.47960(5)

     

    (1)Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $92.973435 per share, at prices ranging from $92.79 to $93.17 per share.

    (4) Reflects a weighted average purchase price of $93.23956 per share, at prices ranging from $92.885 to $93.575 per share.

    (5) Reflects a weighted average purchase price of $93.47960 per share, at prices ranging from $93.40 to $93.53 per share.

     

    Funds

     

    Date  Number of Shares Sold   Price Per Share($) (1)(2) 
    2/26/2021   122    93.20078(3)
    3/2/2021   109    92.98165(4)
    3/25/2021   5,000    93.54767(5)
    3/26/2021   5,000    93.88238(6)
    3/29/2021   3,400    93.53773(7)
    3/30/2021   3,500    93.45746(8)
    3/31/2021   3,535    93.54948(9)
    4/16/2021   1,600    94.14078(10)
    4/19/2021   16,800    94.02001(11)
    4/20/2021   15,200    93.97384(12)
    4/21/2021   17,700    93.96496(13)
    4/22/2021   16,600    94.01163(14)
    4/23/2021   17,300    94.18329(15)

     

    (1)Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average sale price of $93.20078 per share, at prices ranging from $92.64 to $93.55 per share.

    (4) Reflects a weighted average sale price of $92.98165 per share, at prices ranging from $92.74 to $93.22 per share.

    (5) Reflects a weighted average sale price of $93.54767 per share, at prices ranging from $93.33 to $93.775 per share.

    (6) Reflects a weighted average sale price of $93.88238 per share, at prices ranging from $93.73 to $94.13 per share.

    (7) Reflects a weighted average sale price of $93.53773 per share, at prices ranging from $93.38 to $93.92 per share.

    (8) Reflects a weighted average sale price of $93.45746 per share, at prices ranging from $93.41 to $93.51 per share.

    (9) Reflects a weighted average sale price of $93.54948 per share, at prices ranging from $93.24 to $94.03 per share.

    (10) Reflects a weighted average sale price of $94.14078 per share, at prices ranging from $94.05 to $94.38 per share.

    (11) Reflects a weighted average sale price of $94.02001 per share, at prices ranging from $93.79 to $94.22 per share.

    (12) Reflects a weighted average sale price of $93.97384 per share, at prices ranging from $93.8576 to $94.13 per share.

    (13) Reflects a weighted average sale price of $93.96496 per share, at prices ranging from $93.825 to $94.159 per share.

    (14) Reflects a weighted average sale price of $94.01163 per share, at prices ranging from $93.92 to $94.2041 per share.

    (15) Reflects a weighted average sale price of $94.18329 per share, at prices ranging from $93.95 to $94.45 per share.

     

     

    Get the next $MGLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Feld Peter A returned 2,374,798 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:43:07 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form 4: Shulman Steven J returned 27,451 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:22:13 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form 4: West Jeffrey N returned 25,692 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:23:35 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Journey Venture Studio Appoints First Four Board Members

    Notable Seasoned Entrepreneurs Will Support Inaugural Founders-In-Residence Cohort and the Development of Future Disruptive Healthcare Startups in Phoenix PHOENIX, July 24, 2023 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today the appointment of the first four members to its board of directors. Each board member was sought out as a mission-aligned partner as the studio prepares to launch its first Founder in Residence Cohort. The first four board members include: Heidi Jannenga, WebPT Co-founder & Chief Clinical Officer Jason Wood, Managing Director with Morgan Stanley Investment Management's Next Level Fund Andy Lombard, CEO of Arizona Venture Development Corporation (AVC) J

    7/24/23 9:00:00 AM ET
    $CNC
    $MGLN
    Medical Specialities
    Health Care
    Hospital/Nursing Management

    Concerned Shareholders of Cano Health Nominate Highly Qualified, Independent Director Candidates and Propose Removal of Dr. Marlow Hernandez from Board for Cause

    Group Details the Case for Urgent Change at Cano Following an Extended Period of Underperformance, Failed Capital Allocation, and Extremely Poor Governance and Strategic Execution Urges Stockholders to WITHHOLD Support for Incumbent Directors as Parties Await a Resolution of Litigation to Compel Company to Reopen Window for Nominating Director Candidates and Making Proposals Elliot Cooperstone, Lewis Gold and Barry Sternlicht (collectively with certain of their affiliates, the "Group," "us" or "we"), who recently resigned as members of the Board of Directors (the "Board") of Cano Health, Inc. ("Cano" or the "Company") (NYSE:CANO), today announced that they have submitted a notice to the

    5/18/23 9:28:00 AM ET
    $BKD
    $CANO
    $CIVI
    Hospital/Nursing Management
    Health Care
    Medical/Nursing Services
    Oil & Gas Production

    Magellan Health Opens 24-hour Crisis Line for Individuals Impacted by Hurricane Ian

    Consultation and resources available at no cost to local community Magellan Health, Inc. today announced that it has opened a complimentary 24-hour crisis line for individuals impacted by the aftermath of Hurricane Ian. The toll-free number to access free, confidential consultation services is 1-800-327-7451. Magellan confidential consultation services are offered at no charge to the community to assist individuals as they work to cope with the feelings of fear, sadness, anger, or hopelessness related to these kinds of natural disasters. Crisis line callers may also seek information and guidance to other available resources, such as community-based support. Tip sheets with resources spe

    9/29/22 11:00:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    SEC Filings

    View All

    SEC Form 15-12B filed by Magellan Health, Inc.

    15-12B - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/14/22 4:08:42 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by Magellan Health, Inc.

    S-8 POS - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/4/22 4:54:57 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by Magellan Health, Inc.

    S-8 POS - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/4/22 4:52:36 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Leadership Updates

    Live Leadership Updates

    View All

    The Journey Venture Studio Appoints First Four Board Members

    Notable Seasoned Entrepreneurs Will Support Inaugural Founders-In-Residence Cohort and the Development of Future Disruptive Healthcare Startups in Phoenix PHOENIX, July 24, 2023 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today the appointment of the first four members to its board of directors. Each board member was sought out as a mission-aligned partner as the studio prepares to launch its first Founder in Residence Cohort. The first four board members include: Heidi Jannenga, WebPT Co-founder & Chief Clinical Officer Jason Wood, Managing Director with Morgan Stanley Investment Management's Next Level Fund Andy Lombard, CEO of Arizona Venture Development Corporation (AVC) J

    7/24/23 9:00:00 AM ET
    $CNC
    $MGLN
    Medical Specialities
    Health Care
    Hospital/Nursing Management

    Magellan Health Appoints Tom Britt as Chief Information Officer

    Magellan Health, Inc. today announced it has appointed Tom Britt as chief information officer for Magellan Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005111/en/Tom Britt (Photo: Business Wire) Britt will work closely with Magellan's executive leadership to create, develop and implement information technology strategy and digital solutions while leveraging best practices and delivering data-enhanced products and services through innovative technology platforms. "Tom is a strong leader with over 25 years of significant leadership experience in building innovative digital products and solutions while leading high

    8/8/22 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Appoints Dr. Caroline Carney as President of Behavioral Health

      Magellan Health, Inc., one of the nation's leaders in behavioral health, today announced it has appointed Caroline Carney, MD, MSc, FAPM, CPHQ, as president of behavioral health for its subsidiary, Magellan Healthcare. In this key leadership role, Dr. Carney will advance Magellan Health's clinical mission and further position the company's significant leadership capabilities in behavioral health, including collaborative and integrated approaches that enhance member experience across the continuum of care. Dr. Carney will also continue in her role as chief medical officer of Magellan Health, leading the development and implementation of innovative, integrated clinical programs for custo

    2/3/22 4:36:00 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Financials

    Live finance-specific insights

    View All

    Magellan Health Reports Third Quarter 2021 Financial Results

    Magellan Health, Inc. (NASDAQ:MGLN) today announced financial results for the third quarter ended September 30, 2021, as summarized below:             Three Months Ended   Nine Months Ended Sept 30   Sept 30 (In millions, except per share amounts)           Continuing Operations     2021         2020     Chg     2021     2020   Chg Net revenue $   1,254.1     $   1,170.1     7.2 %   $ 3,636.5   $ 3,392.6   7.2 % Net (loss) income $   (0.1 )   $   (17.3 )   NM     $ 21.9   $ 28.7   -23.7 % Segment profit [1] $   38.

    11/5/21 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Reports Second Quarter 2021 Financial Results

    Magellan Health, Inc. (NASDAQ:MGLN) today announced financial results for the second quarter ended June 30, 2021, as summarized below: Three Months Ended     Six Months Ended June 30     June 30 (In millions, except per share amounts)                         Continuing Operations     2021         2020   Chg         2021       2020   Chg Net revenue $   1,220.8     $   1,100.1   11.0 %   $   2,382.4   $   2,222.5   7.2 % Net income (loss) $   (6.5 )   $   47.1   -113.7 %   $   22.0   $   46.0   -52.1 % Segment profit [1]

    8/5/21 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Reports 2020 Financial Results

    PHOENIX--(BUSINESS WIRE)--Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the fourth quarter and the year ended December 31, 2020, as summarized below:   Three Months Ended Twelve Months Ended December 31 December 31 (In millions, except per share amounts) Continuing Operations 2020 2019 Chg 2020 2019 Chg Net revenue $ 1,185.0   $ 1,133.8 4.5 % $ 4,577.5 $ 4,565.6 0.3 % Net (loss) income $ (24.7 ) $ 9.5 NM   $ 4.0 $ 12.6 -67.9 % Segment profit [1] $ 11.3   $ 55.9 -79.8 % $ 14

    2/26/21 4:55:00 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Magellan Health, Inc. (Amendment)

    SC 13D/A - MAGELLAN HEALTH INC (0000019411) (Subject)

    1/6/22 5:18:35 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Magellan Health, Inc.

    SC 13G - MAGELLAN HEALTH INC (0000019411) (Subject)

    7/6/21 2:59:29 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by Magellan Health, Inc. (Amendment)

    SC 13D/A - MAGELLAN HEALTH INC (0000019411) (Subject)

    4/27/21 3:59:03 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care